InnoCan Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.16.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.10.
During the past 12 months, the average EBIT per Share Growth Rate of InnoCan Pharma was -656.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 44.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for InnoCan Pharma's EBIT per Share or its related term are showing as below:
HAM:IP40'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -57.6 Med: 19 Max: 47
Current: 44.2
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of InnoCan Pharma was 47.00% per year. The lowest was -57.60% per year. And the median was 19.00% per year.
HAM:IP40's 3-Year EBIT Growth Rate is ranked better than 85.52% of 1581
companies
in the Consumer Packaged Goods industry
Industry Median: 6.9
vs HAM:IP40: 44.20
InnoCan Pharma's EBIT for the
three
months ended in Mar. 2026 was €-0.71 Mil.
InnoCan Pharma (HAM:IP40) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
InnoCan Pharma EBIT per Share Related Terms
InnoCan Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a EBIT per Share of €-0.10 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #229 out of 1581 companies in the Consumer Packaged Goods industry, placing it in the top 14.5%.
Is InnoCan Pharma's EBIT per Share too high?
InnoCan Pharma's current EBIT per Share is €-0.10. Based on the distribution chart, InnoCan Pharma ranks #229 out of 1581 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's EBIT per Share compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #229 out of 1581 companies for EBIT per Share. This places InnoCan Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Consumer Packaged Goods company?
The median EBIT per Share among Consumer Packaged Goods companies is 6.90, based on 1,581 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median EBIT per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current EBIT per Share is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.23, compared to a current price of €1.47 — trading 84.1% below its estimated fair value. The current EBIT per Share is €-0.10. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current EBIT per Share is €-0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.47 is trading 84.1% below its estimated GF Value™ of €9.23.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
EBIT per Share: €-0.10
GF Value™: €9.23 vs. price of €1.47 (84.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score
Get the complete analysis for HAM:IP40
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
